Systemic sclerosis (scleroderma) trials in France

In France 57 Also abroad 213

57 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Bordeaux, Nantes, Paris, Poitiers, Rennes, Strasbourg, Toulouse
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
No phaseNot yet taking people in France
Small Airway Dysfunction in Rheumatoid Arthritis and Systemic Sclerosis
Where
Paris
Age
18 years and over
People
184
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07924124
No phaseTaking people
Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)
Where
Montpellier
Age
18 years to 85 years
People
16
Run by
University Hospital, Montpellier
See details and how to joinNCT07650565
Phase 3Not yet taking people in France
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
Where
Bordeaux Cedex, Paris, Strasbourg Cedex 2, Toulouse Cedex 9
People
340 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00
No phaseNot yet taking people in France
A Clinical Study on Systemic Sclerosis and the Validation of French-language Questionnaires Assessing Disability, Quality of Life, and Disease Status.
Where
Paris
Age
18 years and over
People
200
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07888842
Phase 2Taking people
SUBCUTANEOUS INJECTIONS OF AUTOLOGOUS CULTURED ADIPOSE-DERIVED STROMA/ STEM CELLS TO HEAL REFRACTORY ISCHEMIC DIGITAL ULCERS IN PATIENTS WITH SCLERODERMA
Where
Caen Cedex 9, Dijon, Grenoble Cedex 9, Lille, Montpellier Cedex 5, Nantes, Toulouse Cedex 9
Age
18 years to 64 years
People
32
Run by
Centre Hospitalier Universitaire De Toulouse
See details and how to join2023-508432-53-00 · EU 2023-508432-53-00
Phase 2Taking people
Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Where
Grenoble, Montpellier Cedex 5, Paris, Strasbourg, Toulouse Cedex 9, Vandoeuvre-lès-Nancy
Age
18 years and over
People
36 worldwide
Run by
Mediar Therapeutics Inc.
See details and how to join2025-523288-39-00 · EU 2025-523288-39-00
Phase 2Taking people
Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy
Where
Lille, Montpellier, Paris, Rouen
Age
18 years to 64 years
People
6
Run by
University Hospital, Montpellier
See details and how to joinNCT07493395
Phase 3Taking people
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Where
Bordeaux, Brest, Caen, Epagny Metz-tessy, Marseille, Nancy Cedex, Nantes, Paris, Rennes, Strasbourg Cedex, Toulouse Cedex 9, Tours Cedex 9
Age
18 years and over
People
448 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00
Phase 1Not yet taking people in France
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Montpellier, Paris
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 2Taking people
A Phase IIa Trial Evaluating the Efficacy of anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs. SCLEROCAR
Where
Lille, Montpellier Cedex 5, Paris
Age
18 years to 64 years
People
6
Run by
Centre Hospitalier Universitaire De Montpellier
See details and how to join2024-519511-33-00 · EU 2024-519511-33-00
Phase 2Taking people
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Where
La Tronche, Montpellier, Paris, Strasbourg, Toulouse, Vandœuvre-lès-Nancy
Age
18 years and over
People
85 worldwide
Run by
Mediar Therapeutics
See details and how to joinNCT07287670
Phase 2Taking people
Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis
Where
Bordeaux, Grenoble Cedex 9, Lille, Paris
Age
18 years and over
People
15 worldwide
Run by
Topadur Pharma AG
See details and how to joinNCT06954597 · EU 2024-511861-12-00
Phase 2Not yet taking people in France
Obinutuzumab in Systemic Sclerosis
Where
Paris
Age
18 years and over
People
120
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07842523
No phaseNot yet taking people in France
Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies
Where
Bron, Lyon, Oullins
Age
6 years to 60 years
People
120
Run by
Hospices Civils de Lyon
See details and how to joinNCT07837986
Phase 3Not yet taking people in France
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Where
Bordeaux, Bron, Paris, Rennes, Strasbourg Cedex 2, Toulouse Cedex 9
Age
16 years and over
People
92 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07335562 · EU 2025-524337-11-00
Phase 2Not yet taking people in France
Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease
Where
Paris
Age
18 years and over
People
120
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT07827742 · EU 2025-521331-36-00
Phase 2Taking people
Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study
Where
Bordeaux, Bron, Le Kremlin-Bicetre, Limoges, Paris, Paris Cedex 10, Paris Cedex 13, Rennes, Rouen Cedex, Toulouse, Toulouse Cedex 9
Age
6 months to 64 years
People
40
Run by
University Hospital, Limoges
See details and how to joinNCT03582800 · EU 2024-511620-13-00
Phase 3Taking people
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Where
Toulouse
Age
18 years and over
People
514 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06716606
Phase 2/3Taking people
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Where
Bobigny, Brest, Paris, Paris Cedex 13, Toulouse Cedex 9
Age
18 years and over
People
300 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01
Phase 1Not yet taking people in France
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
Where
Villejuif
Age
18 years to 75 years
People
6
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07544225
No phaseTaking people
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
Where
Strasbourg
Age
18 years to 70 years
People
200
Run by
University Hospital, Strasbourg, France
See details and how to joinNCT07251179
No phaseTaking people
Periodontal Microbiota in Systemic Sclerosis
Where
Strasbourg
Age
18 years and over
People
30
Run by
University Hospital, Strasbourg, France
See details and how to joinNCT06182293
Phase 2Taking people
Platform Clinical Study for Conquering Scleroderma
Where
Bobigny, Bron, Grenoble Cedex 9, Lille Cedex, Pessac Cedex, Rennes, Strasbourg Cedex, Toulouse
Age
18 years and over
People
400 worldwide
Run by
Scleroderma Research Foundation, Inc.
See details and how to joinNCT06195072 · EU 2023-507129-40-00
Phase 1Taking people
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
Where
Clermont-Ferrand, Créteil, Grenoble Cedex 9, Toulouse Cedex 9
Age
18 years and over
People
51 worldwide
Run by
CRISPR Therapeutics AG
See details and how to join2024-518528-54-00 · EU 2024-518528-54-00